This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Banerjee, A. G. Articles by Vishwanatha, J. K. Search for Related Content PubMed PubMed Citation Articles by Banerjee, A. G. Articles by Vishwanatha, J. K.

Departments of Biochemistry and Molecular Biology [A. G. B., V. K. G., J. K. V.] and Oral Biology [I. B.], University of Nebraska Medical Center, Omaha, Nebraska 68198

Establishment of an early and reliable biomarker for oral carcinogenesis whose expression can be monitored through noninvasive techniques will enable early diagnosis of cancer. Cyclooxygenases (COXs) have been implicated previously in several human malignancies, and the therapeutic benefit of specific COX-2 inhibitors has been elucidated. The expression of COX-2 and subsequent markers of malignant progression was studied in archival human specimens representing premalignant and malignant stages of oral cancer. We find that changes in COX-2 gene expression precede changes in expression of biomarkers related to apoptosis and angiogenesis in oral premalignant tissues as a veritable phenotype. We also report for the first time COX-2 mRNA variants in dysplastic samples and in a human papillomavirus-transformed cell line HOK-16B, indicating a possible stabilization of COX-2 message by human papillomavirus infection as an early event in oral cancer. Expression of other markers of tumor progression related to apoptosis and angiogenesis pathway genes shows relatively low level of changes in oral premalignant tissue. However, a determinant shift toward decrease in antitumor immunity was observed by cytokine gene expression profile changes.

This article has been cited by other articles:

				V. A. Papadimitrakopoulou, W. N. William Jr., A. J. Dannenberg, S. M. Lippman, J. J. Lee, F. G. Ondrey, D. E. Peterson, L. Feng, A. Atwell, A. K. El-Naggar, et al. Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions Clin. Cancer Res., April 1, 2008; 14(7): 2095 - 2101. [Abstract] [Full Text] [PDF]

				R. Wu, A. L. Abramson, M. J. Shikowitz, A. J. Dannenberg, and B. M. Steinberg Epidermal Growth Factor-Induced Cyclooxygenase-2 Expression Is Mediated through Phosphatidylinositol-3 Kinase, Not Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase, in Recurrent Respiratory Papillomas Clin. Cancer Res., September 1, 2005; 11(17): 6155 - 6161. [Abstract] [Full Text] [PDF]

				A. G. Banerjee, I. Bhattacharyya, and J. K. Vishwanatha Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia Mol. Cancer Ther., June 1, 2005; 4(6): 865 - 875. [Abstract] [Full Text] [PDF]

				J. L. Mulshine, J. C. Atkinson, R. O. Greer, V. A. Papadimitrakopoulou, C. Van Waes, S. Rudy, J. W. Martin, S. M. Steinberg, D. J. Liewehr, I. Avis, et al. Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia Clin. Cancer Res., March 1, 2004; 10(5): 1565 - 1573. [Abstract] [Full Text] [PDF]

				A. G. Banerjee, I. Bhattacharyya, W. M. Lydiatt, and J. K. Vishwanatha Aberrant Expression and Localization of Decorin in Human Oral Dysplasia and Squamous Cell Carcinoma Cancer Res., November 15, 2003; 63(22): 7769 - 7776. [Abstract] [Full Text] [PDF]